Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can The FDA Climate Be Too Good?

Executive Summary

US FDA’s decision to accept Amicus’ migalastat NDA without a new study is the latest sign of the positive climate for rare disease drugs at FDA. But will it be remembered as a turning point?

You may also be interested in...



FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch

Amicus plans to file migalastat for Fabry disease in the US in the fourth quarter, after FDA gave the greenlight, reversing a decision last year to require an additional Phase III study. Additional information includes European submission data and post-launch RWE.

Trump Slams FDA Regulations In Joint Session Of Congress

US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.

Robert Califf’s Chance To Make History At The US FDA

Robert Califf’s first tenure as US FDA Commissioner was decidedly anti-climactic. His return trip – assuming the Senate confirms him – will be potentially transformational: he will be the leader that defines what FDA is after COVID.

Topics

UsernamePublicRestriction

Register

PS121117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel